H. Lundbeck Gestione

Gestione criteri di controllo 2/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Charl van Zyl

Amministratore delegato

DKK 39.6m

Compenso totale

Percentuale dello stipendio del CEO	6.8%
Mandato del CEO	1.2yrs
Proprietà del CEO	n/a
Durata media del management	2.3yrs
Durata media del Consiglio di amministrazione	3.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Charl van Zyl rispetto agli utili di H. Lundbeck?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2024	n/a	n/a	DKK 3b
Jun 30 2024	n/a	n/a	DKK 3b
Mar 31 2024	n/a	n/a	DKK 2b
Dec 31 2023	DKK 40m	DKK 3m	DKK 2b

Compensazione vs Mercato: La retribuzione totale di Charl ($USD 5.59M ) è superiore alla media delle aziende di dimensioni simili nel mercato Austrian ($USD 2.50M ).

Compensazione vs guadagni: Dati insufficienti per confrontare la retribuzione di Charl con le performance aziendali.

AMMINISTRATORE DELEGATO

Charl van Zyl (57 yo)

1.2yrs

Mandato

DKK 39,600,000

Compensazione

Mr. Charl van Zyl served as Executive Vice President Neurology Solutions & Head of EU/International at UCB SA since February 2020 until June 2023. He serves as President and Chief Executive Officer of H. L...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Charl van Zyl	President & CEO	1.2yrs	DKK 39.60m	Nessun dato
Joerg Hornstein	CFO & Executive VP of Corporate Functions	2.3yrs	DKK 10.90m	0.0023% € 129.8k
Lars Bang	Executive Vice President of Product Development & Supply	5.8yrs	DKK 10.10m	0.038% € 2.2m
Per Luthman	Executive Vice President of Research & Development	5.8yrs	DKK 11.30m	0.014% € 799.5k
Tarek Samad	Senior VP & Head of Research	3.5yrs	Nessun dato	Nessun dato
Palle Olesen	Chief Specialist & VP of Investor Relations	no data	Nessun dato	Nessun dato
Tine Hansen	Senior Vice President of Corporate Communications & Public Affairs	less than a year	Nessun dato	Nessun dato
Dianne Holto	Executive Vice President of People & Culture	less than a year	Nessun dato	Nessun dato
Ole Chrintz	Senior Vice President of International Markets	no data	Nessun dato	Nessun dato
Rupert Sandbrink	Senior VP & Head of Clinical Development	2.8yrs	Nessun dato	Nessun dato
Bjorn Mogensen	Senior Vice President of Group Finance	2.3yrs	Nessun dato	Nessun dato
Jose Molinuevo	VP & Head of Experimental Medicine	no data	Nessun dato	Nessun dato

2.3yrs

Durata media

58.5yo

Età media

Gestione esperta: Il team dirigenziale di LUNB è considerato esperto (durata media dell'incarico 2.3 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Lars Rasmussen	Independent Chairman	11.8yrs	DKK 1.70m	0.010% € 576.5k
Lene Skole-Sorensen	Deputy Chairman	9.8yrs	DKK 1.20m	0.0062% € 353.4k
Jeffrey Berkowitz	Independent Director	6.7yrs	DKK 1.20m	Nessun dato
Lars Holmqvist	Director	9.8yrs	DKK 600.00k	0.0076% € 432.4k
Jakob Riis	Director	1.7yrs	DKK 450.00k	0.0055% € 312.3k
Ilse Wenzel	Independent Director	3.7yrs	DKK 70.00k	Nessun dato
Santiago Arroyo	Independent Director	3.7yrs	DKK 1.00m	Nessun dato
Camilla Andersson	Employee Representative Director	2.7yrs	DKK 400.00k	0.00010% € 5.7k
Dorte Clausen	Employee Representative Director	2.7yrs	DKK 400.00k	0.00011% € 6.3k
Hossein Armandi	Employee Representative Director	2.7yrs	DKK 400.00k	Nessun dato
Lasse Skibsbye	Employee Representative Director	2.7yrs	DKK 400.00k	Nessun dato

3.7yrs

Durata media

58yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LUNB sono considerati esperti (durata media dell'incarico 3.7 anni).

H. Lundbeck Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

H. Lundbeck A/S Announces Management Appointments

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

Recent updates

Third quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.68 in 3Q 2023)

H. Lundbeck A/S Raises Earnings Guidance for the Year 2024

H. Lundbeck A/S Announces Positive Results from Phase III Pivotal Trial (Sunrise) of Vyepti® (Eptinezumab) in Migraine Prevention

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S (CPSE:HLUN B) signed an agreement to acquire Longboard Pharmaceuticals, Inc. (NasdaqGM:LBPH) for $2.3 billion.

H. Lundbeck A/S Initiates Clinical Trial in Immunology for Lu Ag22515 in Thyroid Eye Disease

H. Lundbeck A/S Presents Results from Two Studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders

Second quarter 2024 earnings released: EPS: kr.0.78 (vs kr.0.60 in 2Q 2023)

Lundbeck and Otsuka Announce FDA Acceptance of sNDA Filing for Brexpiprazole in Combination with Sertraline for the Treatment of Adults with Post-Traumatic Stress Disorder

H. Lundbeck A/S Expands Focus on Neurohormonal Dysfunctions with New Cushing's Disease Trial

Lundbeck Presents Innovative First in Human Trial Design of Lu AG13909 for Potential Treatment of Congenital Adrenal Hyperplasia

H. Lundbeck A/S to Report Q4, 2024 Results on Feb 05, 2025

H. Lundbeck A/S Provides Earnings Guidance for the Year 2024

H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024

Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD

Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia

H. Lundbeck A/S Announces Management Appointments

H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage

Upcoming dividend of kr.0.70 per share

Dividend of kr.0.70 announced

H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023

Less than half of directors are independent

H. Lundbeck A/S Appoints Dianne Holto as EVP, People & Organization, Effective from April 1, 2024

Lundbeck Announces Supportive Phase II Results with Lu Af82422 in the Treatment of Multiple System Atrophy from the Amulet Trial

H. Lundbeck A/S to Report Nine Months, 2024 Results on Nov 13, 2024

H. Lundbeck A/S, Annual General Meeting, Mar 20, 2024

H. Lundbeck A/S Announces New Clinical Data Supporting the Efficacy and Tolerability of Lu AG09222 for the Preventive Treatment of Migraine At the International Headache Congress 2023 in Seoul, Korea

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

Lundbeck and Otsuka Announce Topline Results from Two Phase III Trials of Brexpiprazole as Combination Therapy with Sertraline for the Treatment of Post-Traumatic Stress Disorder in Adults

H. Lundbeck A/S Announces Elise Hauge Executive Vice President, People and Communication Decides to Depart

H. Lundbeck A/S to Report Q4, 2023 Results on Feb 07, 2024

H. Lundbeck A/S Raises Earnings Guidance for the Year 2023

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media